# Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations

> **NCT01206049** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 88 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Panitumumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01206049
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2017-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206049, "Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01206049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*